Search

Your search keyword '"Walewski J"' showing total 505 results

Search Constraints

Start Over You searched for: Author "Walewski J" Remove constraint Author: "Walewski J"
505 results on '"Walewski J"'

Search Results

1. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

3. ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2

4. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study

7. The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study

8. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

9. S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA

15. RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL

16. TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES

18. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) WITH OR WITHOUT TOTAL BODY IRRADIATION (TBI) IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA (MCL) PATIENTS. A RETROSPECTIVE EVALUATION OF 132 PATIENTS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG): PH-O113

20. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant

21. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

27. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

28. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

30. Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma: Evaluation of safety and efficacy in a multicenter study

33. Treatment of Older Patients with Mantle-Cell Lymphoma

36. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European mantle cell lymphoma network (MCL net): V116

42. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients

45. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

46. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R-CHOP AND WERE NOT CANDIDATES FOR HIGH-DOSE THERAPY AND ASCT - PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG-8)

47. PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA. CLINICAL FEATURES AND OUTCOME IN 55 PATIENTS. POLISH LYMPHOMA RESEARCH GROUP STUDY

49. MOLECULAR ANALYSES AND AN INNOVATIVE DIAGNOSTIC ALGORITHM IN MYC -NEGATIVE BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION: A SINGLE INSTITUTION EXPERIENCE

50. S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3-YEAR UPDATE OF THE ECHELON-1 STUDY

Catalog

Books, media, physical & digital resources